Canadian Immunization Research Network
15
3
5
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
53%
8 trials in Phase 3/4
40%
4 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies
Role: lead
Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
Role: lead
Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart
Role: lead
African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
Role: lead
Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students
Role: lead
Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity
Role: lead
Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction
Role: lead
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
Role: collaborator
CT18 Infant Influenza Priming Study in Vaccine Naive Infants
Role: lead
Vaccinating Children After Chemotherapy
Role: lead
Adolescent MenACWY Booster Study
Role: lead
Public Health Messages to Address Vaccine Hesitancy
Role: collaborator
Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization
Role: collaborator
Hepatitis B Booster Study in Adolescence
Role: collaborator
Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults
Role: lead
All 15 trials loaded